Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janeiro 2024 - 9:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome
editing company, today announced that the Company’s President and
CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 42nd Annual
J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, 4:30
p.m. PT / 7:30 p.m. ET in San Francisco, CA.
A live webcast of the presentation will be available on the
“Investors” section of the Editas Medicine website at
www.editasmedicine.com. An archived replay will be available on the
website for approximately 30 days following the presentation.
About Editas MedicineAs a
clinical-stage genome editing company, Editas Medicine is focused
on translating the power and potential of the CRISPR/Cas12a and
CRISPR/Cas9 genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the
world. Editas Medicine aims to discover, develop, manufacture, and
commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive
licensee of Broad Institute’s Cas12a patent estate and Broad
Institute and Harvard University’s Cas9 patent estates for human
medicines. For the latest information and scientific presentations,
please visit www.editasmedicine.com.
Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Editas Medicine (NASDAQ:EDIT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024